Protocol No
ALLIANCE-A052101
Phase
III
Summary
This study is being done to answer the following question:
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Description
This study is being done to answer the following question:
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Participating Institutions
Froedtert Hospital
Moorland Reserve Health Center
Status
IRB INITIAL APPROVAL
Categories
ClinicalTrials.gov